The Russian pharmaceutical market grew by 10% in value terms to 2.85 trillion roubles ($85 billion) in 2024, which was mainly ...

Cambridge, USA-based Merida Bioscienes, a biotechnology company pioneering a new class of precision therapeutics designed to ...

The European Commission (EC) has granted marketing authorization to Rinvoq (upadacitinib; 15mg, once daily), from US pharma ...

US biotech Annovis Bio has reported encouraging findings for its experimental therapy buntanetap in a subgroup of patients ...

US pharma major Bristol Myers Squibb has received full approval from the US Food and Drug Administration for the use of ...

Swiss biopharma Idorsia (SIX: IDIA) has received approval from the US Food and Drug Administration for an updated label on ...

Licensing agreements for Chinese drug candidates hit a record high in 2024, with large pharma in-licensing 28% of innovator drugs from Chinese biopharma companies.

Shares of USA and UK-based KalVista Pharmaceuticals (Nasdaq: KALV) fell 4% to $11.04 yesterday, despite the company revealing it has signed a licensing deal for the commercialization rights in Japan ...